Marathon Pharmaceuticals LLC
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 2008-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://marathonpharma.com
A Open Label Extension Study for Subjects That Complete Study MP-101-CL-001
Phase 3
Withdrawn
- Conditions
- Short Gut SyndromeShort Bowel SyndromeSBSShort Gut
- Interventions
- Drug: 0.6 mL, MP-101 (10 mg/mL, Opium Tincture (OT)), USP (Deodorized)
- First Posted Date
- 2014-09-23
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- Marathon Pharmaceuticals, LLC
- Registration Number
- NCT02246816
- Locations
- 🇺🇸
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Indiana University, Indianapolis, Indiana, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
A Phase III Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Investigational Product MP-101 in Subjects With Short Bowel Syndrome Who Have Had an Inadequate Response to Anti-Diarrheals
Phase 3
Withdrawn
- Conditions
- SBSShort Gut SyndromeShort Bowel SyndromeShort BowelShort Gut
- Interventions
- First Posted Date
- 2014-09-17
- Last Posted Date
- 2015-02-18
- Lead Sponsor
- Marathon Pharmaceuticals, LLC
- Registration Number
- NCT02242656
- Locations
- 🇺🇸
Indiana University, Indianapolis, Indiana, United States
🇺🇸Cleveland Clinic, Cleveland, Ohio, United States
🇺🇸Regional Infectious Diseases Infusion Center, Lima, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath